Strategic IP Support since 1997
Recent Insights & News
When Your IP Becomes a Revenue Line: Three Signals From the Past Week
The most valuable lesson in intellectual property this week wasn’t a single ruling — it was a pattern. Across a landmark licensing deal, a patent that collapsed over one character, and a Congressional hearing on the rules themselves, the same question kept surfacing: is your IP something you defend, or something you monetise? For in-house…
Why Your Site-Blocking Order Isn’t “Set and Forget”: The Discipline Behind Australia’s Piracy Injunctions
If you hold copyright in music, film, software or any content that pirates love, a court order blocking the offending site is one of the most effective tools you have — but only if you treat it as a living instrument, not a trophy. The question every rights holder should be asking is not just…
When a Suffix Isn’t a Shield
A two-letter ending is a thin defence against a deceptively similar mark. The Federal Court’s decision in On Clouds GmbH v Cyclonic, Inc [2026] FCA 647 overturned the Registrar’s delegate and refused registration of CYCLONIC in Classes 25 and 40, finding it deceptively similar to On Clouds’ earlier CYCLON mark. Lenehan J’s analysis is a…
When a Departing Engineer Files a Patent: What Every IP Owner Should Check First
A former engineer leaves, starts a company, and files a patent. Months later the original employer discovers the application describes technology that looks remarkably like a project the engineer worked on internally. This is one of the more under-managed risks in any R&D-heavy business — and a recent Federal Court decision shows just how fast…
The Pharmaceutical Patent Cliff Has a Timetable — And It’s Public
IP Organiser’s recently compiled record of every pharmaceutical patent term extension granted in Australia maps roughly 1,600 extended patents across 850 products, and the patterns are worth reading closely. Activity is concentrated: a handful of originators (Novartis well out in front, then Pfizer, Roche, AstraZeneca and GSK) and just four attorney firms account for around…
